The findings reviewed by GME stated that the Global Biologics Contract Manufacturing Market will expand with a CAGR value 8.2%. Increasing incidences of cancer and other chronic diseases have increased the demand for pharmaceutical drugs in the market. Increased production costs due to government regulations on clinical trials and other costs have resulted in pharmaceutical companies outsourcing production from development stages to drug dose selection to manufacturing to packaging.
Browse 159 Market Data Tables and 119 Figures spread through 189 Pages and in-depth TOC on "Biologics Contract Manufacturing Market - Forecast to 2026"
By Product (Monoclonal Antibodies, Vaccines, Growth Factors, Interferons, Recombinant Hormones, Insulin, Others), By Platform (Mammalian, Microbial), By Application (Clinical, Commercial),By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis
Key Market Insights
· Biologics are bioengineered protein-based drugs that are sourced from organic materials like mammalian and microbial sources.
· The pharmaceutical companies outsource drug production to biologic contract manufacturing vendors due to increasing drug production cost.
· In terms of market value or revenue, the largest shareholder as per platform outlook was the microbial segment in 2020.
· Lonza Group, BioXcellence, AG Samsung Biologics Co. Ltd., AbbVie Contract Manufacturing, Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings), WuXi Biologics Inc., AGC Biologics, Ajinomoto Bio-Pharma, Patheon N.V., Emergent BioSolutions Inc., Avid Bioservices Inc., Catalent Inc., KBI Biopharma, and Abzena Plc, among others, are the major vendors competing in the biologics contract manufacturing market.
Browse the Report @ https://www.globalmarketestimates.com/market-report/global-biologics-contract-manufacturing-market-2773
Product Outlook (Revenue, USD Billion, 2021-2026)
· Monoclonal Antibodies
· Growth Factors
· Recombinant Hormones
Platform Outlook (Revenue, USD Billion, 2021-2026)
Application Outlook (Revenue, USD Billion, 2021-2026)
Regional Outlook (Revenue, USD Billion, 2021-2026)
Rest of Europe
Rest of APAC
Central & South America
Rest of CSA
Middle East & Africa
Rest of MEA
Contact: Tracy Simon
Email address: email@example.com
Phone Number: +16026667238
Website: Global Market Estimates
Next-Gen Expertise About Us
Biologics Contract Manufacturing Market: Insights
Biologics are bioengineered protein-based drugs that target specific areas of the immune system.
Biologic drugs are different from chemically synthesized drugs as biologics are manufactured from
organic sources. Growing instances of chronic diseases and viral outbreaks of H1N1, COVID, among
others have increased the need for biological drugs in the market. Companies have to meet the
growing demand and are slowly beginning to outsource various stages of pharmaceutical
manufacturing from development and innovation to contract to manufacture. Governments are also
incentivizing the development of pharmaceutical drug manufacturing facilities. For instance, the
Singaporean government attracted biologic contract manufacturing investment of around USD 1
billion. Small and medium-sized companies are often unable to bear the costs of having an in-house
manufacturing facility with state-of-the-art equipment. Companies have to conduct clinical trials,
manufacture the drugs and then distribute them, if a product fails in the market the cost incurred will
be high. Biological contract manufacturers conduct clinical trials for the company, manufacture, and
package the product for their client company. The increasing regulations and increased clinical trials
required before a drug can be released have also increased the demand for contract manufacturing.
The biologic contract manufacturing market is driven by the increasing number of small and medium
pharmaceutical manufacturing companies, strict regulations by governments, increased incidences of
chronic diseases and viral outbreaks, increasing drug production cost, and the growing demand for
pharmaceutical drugs. Biologic contract manufacturing companies offer companies their dedicated
equipment which can be utilized by the client at their convenience, this gives the clients access to